VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TVTXTravere Therapeutics, Inc.
$58.85$5.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTVTXPrice Target
TVTX logo

Travere Therapeutics, Inc. (TVTX) Price Target Analysis

Updated Jun 26, 2026
Analyst Rating: Buy
Based on 18 analysts

2.5% Below Target

TVTX trades 2.5% below Wall Street's consensus target of $60.33.

Current Price$58.85
Average Target$60.33
Target
Current
Low$49.00
Median$65.00
High$67.00

Analyst Target Range

Forward P/E301.5x
(High Premium)
PEG Ratio—
Implied Growth+183.7%
(High Growth)
Analyst Spread29.8%
(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$58.85
Consensus$60.33
High$67.00
Low$49.00

Consensus Scenario Assumptions

The base valuation assumes TVTX achieves its forward estimates and maintains a stable P/E multiple of 301.5x. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 18 published analyst recommendations for TVTX

15/18 analysts are bullish
+42
BearishBullish
Weighted analyst sentiment score based on 18 ratings
ConsensusBuy
Coverage18 Analysts
Net Score+42
Bull / Bear83% / 0%
Strong Buy00%
Buy1583%
Hold317%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
1583%
Hold
317%
Sell
00%
Strong Sell
00%
Recommendation Mix83% Buy · 17% Hold · 0% Sell
Buy (15)Hold (3)Sell (0)

TVTX Price Target Analysis

Updated June 28, 2026

As of June 28, 2026, Travere Therapeutics, Inc. (TVTX) has a Wall Street consensus price target of $60.33, based on estimates from 18 covering analysts. With the stock currently trading at $58.85, this represents a potential upside of +2.5%. The company has a market capitalization of $5.47B.

Analyst price targets range from a low of $49.00 to a high of $67.00, representing a 30% spread in expectations. The median target of $65.00 differs from the mean, suggesting potential outlier estimates.

The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, TVTX trades at a trailing P/E of -105.1x and forward P/E of 301.5x. Analysts expect EPS to grow +183.7% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+29.9%
Industry Consensus
Avg Forward P/E
46.5x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
RARE logo
RAREUltragenyx Pharmaceutical Inc.
$3.0B$30.77$48.36
+57.2%
Buy—33
FOLD logo
FOLDAmicus Therapeutics, Inc.
$4.5B$14.49$14.50
+0.1%
Buy40.6x24
ACAD logo
ACADACADIA Pharmaceuticals Inc.
$4.3B$25.32$33.67
+33.0%
Buy65.1x37
PTCT logo
PTCTPTC Therapeutics, Inc.
$7.0B$84.43$95.83
+13.5%
Buy95.3x26
KRYS logo
KRYSKrystal Biotech, Inc.
$11.0B$372.25$336.40
-9.6%
Buy48.5x17
RCKT logo
RCKTRocket Pharmaceuticals, Inc.
$355M$3.25$5.00
+53.8%
Buy—19
ALNY logo
ALNYAlnylam Pharmaceuticals, Inc.
$38.9B$291.37$454.27
+55.9%
Buy38.9x52
IONS logo
IONSIonis Pharmaceuticals, Inc.
$13.4B$81.18$106.50
+31.2%
Buy—32
VRTX logo
VRTXVertex Pharmaceuticals Incorporated
$125.0B$491.34$553.93
+12.7%
Buy25.5x56
BMRN logo
BMRNBioMarin Pharmaceutical Inc.
$11.3B$59.00$89.21
+51.2%
Buy11.9x41

TVTX — Frequently Asked Questions

Quick answers to the most common questions about buying TVTX stock.

What is the TVTX stock price target for 2026?

The consensus price target for TVTX is $60.33, close to the current price of $58.85 (2.5% implied move). Based on 18 analyst estimates, the stock appears fairly valued near current levels.

Is TVTX a buy, sell, or hold?

TVTX has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $60.33 implies 2.5% upside from current levels.

Is TVTX stock overvalued or undervalued?

At a forward P/E of 301.4857x, TVTX trades at a premium valuation. The consensus price target of $60.33 (2.5% upside) suggests analysts may view current valuations as stretched.

How high can TVTX stock go?

The most bullish Wall Street analyst has a price target of $67 for TVTX, while the most conservative target is $49. The consensus of $60.33 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover TVTX stock?

TVTX is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the TVTX stock forecast?

The 12-month TVTX stock forecast based on 18 Wall Street analysts shows a consensus price target of $60.33, with estimates ranging from $49 (bear case) to $67 (bull case). The median consensus rating is "Buy".

What is TVTX's forward P/E ratio?

TVTX trades at a forward P/E ratio of 301.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy TVTX stock?

TVTX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $60.33 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do TVTX price targets vary so much?

TVTX analyst price targets range from $49 to $67, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $60.33 consensus represents the middle ground.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare